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Accumulating evidence suggests that glutamatergic signalling and synaptic plasticity underlie 
one of a number of ways psychiatric disorders appear. The present study reveals a possible 
mechanism by which this occurs, through highlighting the importance of LMTK3, in the 
brain. Behavioural analysis of Lmtk3-KO mice revealed a number of abnormalities that have 
been linked to psychiatric disease such as hyper-sociability, PPI deficits and cognitive 
dysfunction. Treatment with clozapine suppressed these behavioural changes in Lmtk3-KO 
mice. As synaptic dysfunction is implicated in human psychiatric disease, we analysed the 
LTP of Lmtk3-KO mice and found that induction is severely impaired. Further investigation 
revealed abnormalities in GluA1 trafficking after AMPA stimulation in Lmtk3-KO neurons, 
along with a reduction in GluA1 expression in the post-synaptic density. Therefore, we 
hypothesize that LMTK3 is an important factor involved in the trafficking of GluA1 during 
LTP, and that disruption of this pathway contributes to the appearance of behaviour 



















LMTK3 is a member of the Lemur tyrosine kinase (LMTK) family of serine/threonine 
protein kinases, expressed predominantly in the brain. The other family members, LMTK1 
and LMTK2, are reportedly involved in regulating endocytosis. For example, LMTK1 
regulates the movement of recycling endosomes via Rab11A and influences dendrite 
development and axon outgrowth (Takano et al., 2012; Takano et al., 2014). Whereas 
LMTK2 is critical for transitioning early endosomes to recycling endosomes through binding 
of the motor protein, Myosin VI (Inoue et al., 2008). Despite its high expression in the brain, 
little is known about the physiological role of LMTK3. We previously found that Lmtk3-KO 
mice exhibit hyperactivity and reduced anxiety with slightly increased amounts of 
intracellular NMDA receptors (Inoue et al., 2014). We hypothesized that the abnormal 
behaviour of Lmtk3-KO mice could be linked to changes in synaptic function. A number of 
psychiatric diseases, most prominently schizophrenia and bipolar disease are thought to be 
synaptopathies, a disease of the brain or nervous system related to dysfunctional synapses. 
This is due to patients with these particular psychiatric diseases bearing mutations in a 
number of genes associated with synaptic development and function (Du et al., 2011; Forero 
et al., 2009; Stephan et al., 2006). Symptoms of these diseases often overlap, and recent 
reports have shown that this maybe a consequence of shared genetic risk factors (Doherty & 
Owen, 2014; Gandal, 2018). Increasing evidence has led to the hypothesis that dysfunctional 
glutamatergic synaptic transmission is a factor in many brain related disorders including 
schizophrenia and mood disorders (Jun et al., 2014; Konradi & Heckers, 2003; Rubio et al., 
2012). AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid)-type glutamate 
receptors (AMPARs) mediate fast excitatory neurotransmission, and the internalization or re-
insertion of AMPAR subunits at post-synaptic sites regulates long-term potentiation (LTP) or 
long-term depression (LTD) (Henley & Wilkinson, 2013; Huganir & Nicoll, 2013). A 
number of reports have revealed abnormal expression of AMPARs in post-mortem brain 
samples from patients diagnosed with schizophrenia and bipolar disease suggesting an 
important pathological role for these glutamate receptors (Corti et al., 2011; Heckers & 
Konradi, 2002; Meador-Woodruff et al., 2001). In this study, we further analysed the 
behaviour of Lmtk3-KO mice and discovered that they exhibited changes in behaviour and 
memory commonly associated with psychiatric disease. Treatment with clozapine, an 
antipsychotic primarily used to treat schizophrenia patients, but which is also effective for 
bipolar disease (Fehr et al., 2005; Frye et al., 1998) and suggested  for ASD patients (Beherec 
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et al., 2011; Rotharmel et al., 2018), attenuated the abnormal behaviour of Lmtk3-KO mice. 
As synaptic dysfunction is relevant to the behaviour displayed by Lmtk3-KO mice, we 
conducted electrophysiological studies and discovered that LTP is disrupted in Lmtk3-KO 
mice. Further investigation revealed that trafficking of AMPARs, which can directly 
influence LTP, is altered by the loss of LMTK3. Cultured neurons derived from Lmtk3-KO 
mice display abnormal surface and intracellular expression of the AMPAR subunit, GluA1, 
after stimulation with the excitatory neurotransmitter, AMPA. Analysis of forebrain tissue 
revealed a reduction of GluA1 expression in the post-synaptic density of Lmtk3-KO mice. We 
propose that LMTK3 plays a role in the trafficking of GluA1 during synaptic plasticity, 
particularly LTP, which is required for regulating behaviour and cognitive function.  
 
Materials and Methods 
Animals 
Lmtk3-KO mice have a C57BL/6J genetic background. The generation and validation of 
Lmtk3 KO mice is described by Inoue et al 2014. Mice were housed at a constant temperature 
(23±1°C) and kept under a 12-h light/dark cycle.  
Behavioural analysis 
Behavioural experiments were performed with wild type (WT) and knockout (Lmtk3-/-) male 
littermates (8-12 weeks old). All recordings were blind with regard to genotype. For 
clozapine treatments, littermates were randomly distributed to control and treatment groups. 
Clozapine (Sigma) was dissolved in DMSO:saline (1:6), and mice were IP injected with a 
dose of 2 mg/kg. Control mice were injected with DMSO:saline at equivalent volumes. 
Behavioural assays were conducted 30 min after injection. All animal experiments were 
performed following the guidelines for animal use issued by the Animal Ethics Committee, 
Okinawa Institute of Science and Technology. 
Three-chamber social interaction test 
Mice were placed in a three-chamber box (61 cm width x 40 cm length x 22 cm height) with 
removable partitions separating the box into left, right, and centre chambers. The left and 
right chambers contained small cages able to hold single mice. Age- and gender-matched 
C57BL/6J mice (JapanSLC) were used as novel partners. First, test mice were habituated in 
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the chamber for 10 min. Next, a novel mouse was placed in one of the cages and test mice 
were allowed to explore the chambers for 10 min. Immediately after, the social novelty trial 
was conducted for a further 10 min, with a new mouse being placed in the second empty 
cage. Total movement and time spent in close interaction with mice in cages were recorded 
and automatically measured with TimeSCI software (O’hara & Co).   
Novel object recognition test 
The novel object recognition apparatus consisted of an open-field box illuminated at 100 lux. 
During the training session, mice were placed in the apparatus in the presence of two 
identical objects and allowed to explore for 10 min. After a retention interval of 24 h, mice 
were again placed inside the apparatus for 10 min, with one of the previous objects replaced 
with a novel object. The duration of time mice spent interacting with each object was 
recorded and measured with Image SCI software (O’hara & Co). 
Pre-pulse inhibition of the acoustic startle response 
Mice were restrained in a Plexiglas chamber (O’hara & Co)and acclimated to experimental 
conditions for 2 min. The startle response was recorded for 200 ms after onset of the 
stimulus. The peak startle amplitude during the 200 ms sampling window was recorded as a 
measure of the startle response. Background noise level was at 70 dB. A test session 
consisted of a habituation block where a startle stimulus (120 dB) was presented four times 
with random inter-trial times (10-20s). The second block, conducted immediately after the 
first, consisted of 4 prepulse trial types, where a pre-pulse sound (75, 80 or 85 dB) or no 
prepulse was presented 100 ms before the startle stimulus (120 dB). Trials were 
pseudorandomized and presented 8 times each, with inter-trial intervals of (10-20s). The 
following formula was used to calculate the percentage of pre-pulse inhibition of the startle 
response, 100-(100 x (startle response after pre-pulse/startle response alone).  
Morris water maze 
The Morris water maze test was performed in a circular pool (30 cm height x 100 cm in 
diameter), filled with water at a temperature of 22-24°C, made opaque with non-toxic white 
paint. The pool was divided into four quadrants and a white platform was placed in the 
middle of one of the quadrants, 1 cm below the water surface. One day prior to testing, mice 
were allowed to swim for 60 s in the pool with the platform visible with a flag marker. In the 
hidden platform test, three trials per day with inter-trial intervals of 30 min were conducted 
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for six consecutive days. The latency to reach the platform for each trial was recorded with a 
cut-off time of 60 s. Twenty-four hours after the final training day, the platform was removed 
and the probe test was conducted for 60 s. The time spent in each quadrant, and number of 
crossings of the target site was recorded. In the visible platform test, three trials per day with 
inter-trial intervals of 30 min were conducted for three consecutive days. The platform was 
clearly marked with a flag in each trial. The latency to find the platform was recorded with a 
cut-off time of 60 sec. All recordings and measurements were conducted using Time MWM 
software (O’hara & Co).   
Eight-arm radial maze 
The eight-arm radial maze consisted of a central chamber and eight arms with a door at the 
entrance of each arm, which opened and shut automatically, according to the movement of 
mice. Mice used in this test had undergone restriction feeding until ~20% of body weight was 
lost. The day before testing, mice were habituated to the maze by being allowed to roam the 
chambers for 15 min. During the testing phase, a food pellet was placed at the end of each of 
the eight arms, and mice were allowed to explore for 15 min. After four food pellets were 
consumed, a delay was implemented with mice restricted to the central chamber for 1 min. 
The testing phase was conducted once a day for six consecutive days. Latency to consume all 
food pellets, number of entries into each arm and number of entries before repeat entry was 
automatically recorded and measured using Time ERM software (O’hara & Co).  
Y-maze 
Mice were placed in one arm of a three arm maze, illuminated at 50 lux, and the entry 
sequence into each arm and number of arm entries were recorded using Time YM (O’hara & 
Co) software for 10 min. The percentage of triads in which all arms were represented was 
recorded as an alternation. The alternation score (%) was calculated using the following 
equation: number of alternations/total arm entries -2 x100.  
Open-field test 
Mice were placed in the centre of an open-field apparatus (50 cm width x 50 cm depth x 33.3 
cm height) illuminated at 150 lux and allowed to move freely for 15 min. The total distance 
travelled, rearing activity, and time spent in specific areas of the open field were recorded and 
analysed with Time OFCR software (O’hara & Co).  
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Elevated plus maze test 
The elevated plus maze consists of two open arms and two closed arms (25 cm length x 5 cm 
width) extending from a central area (5 x 5 cm) and is elevated 50 cm from the ground. Mice 
were placed in the central area and allowed to move freely for 10 min. The number of entries 
into open or closed arms and time spent in each arm was recorded and analysed using Time 
EPC software (O’hara & Co). 
Light/dark transition test 
The light-dark box consisted of two compartments: a white polyvinylchloride chamber 
illuminated at 500 lux and a black polyvinylchloride chamber with no illumination (19 x 19 x 
19 cm). The two boxes were separated by a vertical sliding door that remained open. Mice 
were placed in the dark chamber and allowed to explore freely for 15 min. The amount of 
time spent in each chamber and the number of transitions between chambers were recorded 
and analysed using Time LD software (O’hara & Co.). 
Contextual and auditory fear conditioning tests 
Fear conditioning was conducted in a small conditioning chamber within a sound attenuating 
chest (CL-M3; O’hara & Co.). On day 1, mice were placed in the conditioning chamber for 
170 s and then presented with a 65dB/10kHz tone for 10 s followed by a foot shock (2s/0.35 
mA). The mice were returned to their home cages after 1 min. On day 2, mice were placed in 
the conditioning chamber for 6 min. On day 3, the mice were placed in a novel chamber for 3 
min and then presented with a tone for 3 min. Freezing responses were recorded during each 
test and analysed using Image FZC 2.22sr2 software (O’hara & Co.). 
Antibodies 
To generate polyclonal antibodies against LMTK3, a fragment of human LMTK3 (aa 1000–
1100) was used as an immunogen. Antibodies were purified by affinity chromatography from 
sera of immunized rabbits. Commercially available antibodies used are as follows: mouse 
anti-GluR1 N-terminal (Millipore); rabbit anti-phospho-GluR1 (Ser845), rabbit anti-GluR2, 
rabbit anti-beta actin (Cell signalling); mouse anti-synaptophysin (Sigma); mouse anti-PSD-
95 (Affinity Bioreagents); goat anti-mouse-Alexa488 and anti-mouse-Alexa555 (Invitrogen). 
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Cell culture and ‘antibody feeding’ immunocytochemistry 
Cortical neurons were prepared from 16-18 day mouse embryos, and cultured according to a 
standard protocol (Inoue et al., 2014). Cultured neurons grown on glass-bottomed dishes 
(MatTek) were fixed with 4% PFA in PBS and permeabilized with 0.2% Triton X-100 in 
PBS before labelling with fluorescent secondary antibodies. The ‘antibody feeding’ method 
was conducted according to published methods (Lin et al., 2000). Images were acquired using 
a scanning confocal microscope (Leica TCS-SP8). 
Surface biotinylation of cultured neurons 
Primary cortical and hippocampal neuronal cultures at DIV14 were treated with 100 µm 
AMPA (Santa Cruz) for various lengths of time, and then immediately placed on ice. Surface 
proteins were biotinylated with 1 mg/mL sulfo-NHS-SS cleavable biotin (Pierce) for 20 min 
at 4°C. Cells were washed with PBS supplemented with 1 mM MgCl2 and 0.1 mM CaCl2 
(PBS/MC) and cells were then lysed with lysis buffer (120 mM NaCl, 50 mM Tris, 5 mM 
EDTA, 1% NP40, 0.1% sodium deoxycholate, 1mM Na3VO4 and protease inhibitor cocktail 
(Nacalai Tesque). Biotinylated proteins were precipitated with Neutravidin resins (Pierce). To 
collect internalized proteins, neurons were biotinylated by the same method as above, then 
subjected to treatment with AMPA and returned to 37°C for described times. Neurons were 
then rapidly cooled to 4°C, and washed with PBS/MC. Biotinylated surface proteins were 
cleaved with cleavage buffer (50 mM glutathione, 75 mM NaCl, 10 mM EDTA, 1% BSA and 
0.075 N NaOH), and biotinylated proteins precipitated.  
Biochemical fractionation 
Mouse brains were homogenized in ice-cold HEPES buffer (0.32M sucrose, 10 mM HEPES 
pH 7.4, 2 mM EDTA and protease inhibitors) using a Dounce homogenizer. The homogenate 
was centrifuged at 1000 x g, and supernatant was removed and re-centrifuged at 12,500 x g to 
obtain a crude synaptosomal fraction (P2). The P2 fraction was lysed hypo-osmotically and 
centrifuged at 25,000 x g to yield a synaptosomal membrane fraction. The post-synaptic 
density fraction (PSD) was obtained by treating the synaptosomal membrane fraction with 
HEPES buffer containing 1% Triton X-100 and centrifugation at 32,000 x g.  
Electrophysiological analysis 
Standard procedures and solutions were used to prepare hippocampal slices (400 μM thick) 
from 10–17 week-old wild-type and Lmtk3-KO mice (Bongsebandhu-phubhakdi & Manabe, 
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2007). Synaptic responses were recorded at 25.0 ± 0.5°C with extracellular field-potential 
recordings in the stratum radiatum of the CA1 region. External solution contained (in mM): 
119 NaCl, 2.5 KCl, 1.3 MgSO4, 2.5 CaCl2, 1.0 NaH2PO4, 26.2 NaHCO3, 11 glucose and 0.1 
picrotoxin, a GABAA-receptor antagonist (Sigma). To evoke synaptic responses, Schaffer 
collateral/commissural fibers were stimulated at 0.1 Hz with a bipolar tungsten electrode. 
Stimulus strength was adjusted to evoke EPSPs with a slope value of 0.10–0.15 mV/ms. A 
recording glass electrode was filled with 3 M NaCl. LTP was induced by 10 trains of theta-
burst stimulation (TBS) at 10 sec intervals. One train of TBS consisted of 5 bursts at 5 Hz, 
and each burst comprised 4 pulses at 100 Hz. An Axopatch-1D amplifier (Molecular Devices, 
Union City, CA, USA) was used to record synaptic responses. Data were filtered at 1 kHz, 
digitized at 10 kHz with Digidata 1440A (Molecular Devices) and analyzed on-line and off-
line using pClamp software (Molecular Devices).  
Statistical analysis 
All data are expressed as means ± SEMs. We used Student’s t-test for biochemical analysis. 
To analyse behavioural data, we used two-way/two-way repeated-measures ANOVA and 
Student’s t-test as indicated. Significant ANOVAs were followed up with Bonferroni's post-
hoc test. Values with p < 0.05 were considered significant. 
 
Results 
Lmtk3-KO mice exhibit altered behavioural patterns 
Having previously observed that Lmtk3-KO mice exhibit hyperactivity and reduced anxiety, 
we analysed whether other behaviours commonly found in mouse models of psychiatric 
disease are also exhibited. Social behaviour was tested using a three-chamber social 
interaction test. During habituation, there was no preference for either of the empty cages 
present in the left and right chambers (F(1,36) = 2.035, p = 0.1624 for genotype effect and 
F(1,36) = 0.2001, p = 0.6573 for cage effect) (Fig. 1A). When a stranger mouse was placed in 
one of the empty cages, Lmtk3-KO mice interacted with the stranger mouse longer than WT 
(F(1,36) = 4.34, p < 0.043 for genotype effect; post-hoc analysis, p = 0.0016 for interaction 
time with stranger mouse) (Fig. 1B). During the social novelty test, Lmtk3-KO mice spent 
equal time interacting with stranger and familiar mice, indicating impaired social memory 
and novelty (F(1,36) = 17.26, p < .0002 for genotype x test mouse interaction; post-hoc 
analysis, p < 0.0001 for interaction time of WT mice) (Fig. 1C). To confirm loss of novelty, 
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we performed the novel object recognition test and found that both genotypes spent equal 
time between two novel objects (F(1,28) = 0.1101, p = 0.74 for genotype effect; F(1,28) = 0.0994, 
p = 0.75 for genotype x object interaction) (Fig. 1D). When one object was replaced with a 
novel object, WT mice interacted longer with the novel object (F(1,28) = 8.681, p < 0.0064 for 
genotype effect; F(1,28) = 8.265, p < 0.05 for genotype x object interaction; post-hoc analysis, 
p = 0.011 for interaction time of WT mice) (Fig. 1E). The prepulse inhibition (PPI) of Lmtk3-
KO mice was previously analysed during the acoustic startle response test, and results 
showed only a slight reduction (Inoue et al., 2014). Here we repeated the PPI test 
independently from the acoustic startle response test, as a number of reports have shown that 
the baseline stimulus can effect PPI, and exposure to different baseline stimuli which occurs 
during the acoustic startle response test can lead to inaccurate results (Sandner & Canal, 
2007; Shoji & Miyakawa, 2018). What we found was that the PPI response in Lmtk3-KO 
mice is significantly attenuated for three different prepulse intensities (F(1,42) = 24.20, p < 
0.0001 for genotype effect; post-hoc analysis, p = 0.0399 for 75dB, p = 0.0019 for 80 dB, p = 
0.014 for 85dB) (Fig. 1F). There was no significant difference in the acoustic startle response 
between genotypes to the single baseline stimulus (120 dB) used, as previously shown (F(1,14) 
= 0.04, p = 0.844 for genotype effect) (Fig. 1G).  




Figure 1. Lmtk3-KO mice exhibit changes in sociability, novel recognition and PPI 
(A-C) Three-chamber social interaction test. (WT, n = 12; KO, n = 12). **P < 0.01, ****P < 
0.0001, (ns) not significant; two-way ANOVA followed by Bonferroni’s test. (A) During 
habituation, there is no preference for a particular cage by either genotype (B) Lmtk3-KO 
mice interact longer with stranger mice than WT after 10 min. (C) Lmtk3-KO show no 
preference for stranger or familiar mice after 10 min. (D-E) Novel object recognition test. 
(WT, n = 8; KO, n = 8). *P < 0.05, (ns) not significant; two-way ANOVA followed by 
Bonferroni’s test. (D) No differences were observed between genotypes in interaction time 
with two novel objects. (E) WT spend more time interacting with a novel object, whereas 
Lmtk3-KO exhibit no preference. (F-G) Pre-pulse inhibition test. (WT, n = 8; KO, n = 8). **P 
< 0.01, *P < 0.05; two-way ANOVA followed by Bonferroni’s test. (F) Lmtk3-KO exhibited 
impaired pre-pulse inhibition (PPI) at three pre-pulse intensities. (G) No difference is found 
in the startle response to the base stimuli of 120 dB by either genotype. All values represent 
means ± SEM. 
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Lmtk3-KO mice display cognitive dysfunction 
Next, we assessed the cognitive function of Lmtk3-KO mice. During the Morris water maze, 
Lmtk3-KO mice failed to find the hidden platform, even after six training days (F(1,14) = 9.944, 
p = 0.0070 for genotype effect; F(5,70) = 2.829, p = 0.0220 for genotype x day) (Fig. 2A). In 
the probe test conducted 24 hrs after the final training day, Lmtk3-KO mice performed 
poorly, with fewer crossings of the trained platform position (t-test p = 0.030) and less time 
spent in the trained quadrant compared to WT mice (t-test p = 0.024) (Fig. 2B, 2C). No 
difference between WT and Lmtk3-KO mice in the visible water maze test was observed (Fig. 
2D). The Y-maze test revealed Lmtk3-KO mice have a deficit in short-term working memory, 
with Lmtk3-KO mice producing significantly fewer spontaneous alternations (t-test p = 
0.004) (Fig. 2E). Lmtk3-KO mice also exhibited a lack of learning and memory in the eight 
arm radial maze test, as there were more errors made by Lmtk3-KO mice over 7 days of 
training (F(1,14) = 5.137, p = 0.039 for genotype effect; F(6,84) = 2.515, p = 0.0275 for genotype 
x day) (Fig. 4F). Working memory span capacity, which was measured as the number of arms 
entered before a repeat entry, was also lower in Lmtk3-KO mice (F(1,14) = 12.22, p < 0.001 for 
genotype effect; F(6,84) = 4.112, p = 0.0011 for genotype x day) (Fig. 2G).  
 




Figure 2. Lmtk3-KO mice exhibit cognitive dysfunction 
(A-C) Morris water maze. (WT, n = 8; KO, n = 8). **P < 0.01, *P < 0.05; two-way repeated 
measures ANOVA (Fig. A) and un-paired two tailed t-test (Fig. B, C). (A) Lmtk3-KO show 
no improvement in latency during training (results shown are the means of three trials). (B) 
The probe test conducted 24 h after final training day shows fewer crossings of the trained 
platform position by Lmtk3-KO. (C) Less time is spent in the trained quadrant by Lmtk3-KO. 
(D) Visible water maze. (WT, n = 8; KO, n = 8). There is no difference in latency to locate a 
visible platform between WT and Lmtk3-KO mice. (E) Y-maze. (WT, n = 10; KO, n = 10). 
**P < 0.01; un-paired two tailed t-test. Lmtk3-KO produce fewer spontaneous alternations in 
10 min. (F-G) Eight-arm radial maze. (WT, n = 8; KO, n = 8). **P < 0.01, *P < 0.05; two-
way repeated measures ANOVA. (F) Lmtk3-KO are more prone to committing working 
memory errors than WT over 7 training days. (G) Lmtk3-KO have a lower working memory 
span. All values represent means ± SEM 
© 2019. This manuscript version is made available under the CC-BY-NC-ND 4.0 
license http://creativecommons.org/licenses/by-nc-nd/4.0/ 
 
Clozapine suppresses the behavioural changes of Lmtk3-KO mice 
A number of psychiatric mouse models display behaviour similar to that of Lmtk3-KO mice, 
primarily models for schizophrenia and bipolar disorder (Cosgrove et al., 2016; Jones et al., 
2011; Leo & Gainetdinov, 2013). Human patients and animal models of these diseases have 
been known to respond to treatment with antipsychotics, therefore we treated Lmtk3-KO mice 
with clozapine which is prescribed to treat a range of psychiatric diseases (Fehr et al., 2005; 
Li et al., 2015; Remington et al., 2016; Siskind et al., 2016). Mice were treated with IP 
injections of clozapine (2 mg/kg) and behavioural testing was conducted 30 min later. The 
locomotor activity of Lmtk3-KO mice compared to vehicle-treated Lmtk3-KO mice during 
the open field test was lower (F(1,28) = 2.731, p < 0.0001 for genotype effect; F(1,28) = 36.61, p 
< 0.0001 for drug effect; F(1,28) = 6.673, p = 0.015 for drug x genotype; post-hoc analysis, p = 
< 0.0001 for KO vehicle vs. KO clozapine) (Fig. 3A). Hyperactivity was not fully suppressed 
in Lmtk3-KO treated mice, which could be due to the drug dose required to completely block 
hyperactivity being higher than what was administered in this study (McOmish et al., 2012). 
We were unable to increase the dosage of clozapine as initial trials revealed higher doses led 
to extreme sedation in Lmtk3-KO mice. Time spent in the centre region by Lmtk3-KO mice 
was similar to that of WT after treatment (F(1,28) = 10.84, p < 0.0027 for genotype effect; 
F(1,28) = 3.057, p = 0.0913 for drug effect; F(1,28) = 12.93, p = 0.0012 for drug x genotype; 
post-hoc analysis, p = 0.0002 for WT vs. KO vehicle, p = 0.0045 for KO vehicle vs. KO 
clozapine), as Lmtk3-KO mice remained active only around the periphery of the open field 
(Fig. 3B). The rearing number of Lmtk3-KO mice was reduced, indicating a recovery from 
the anxiolytic effect of LMTK3 depletion (F(1,28) = 22.66, p < 0.0001 for genotype effect; 
F(1,28) = 11.01, p = 0.0025 for drug effect; F(1,28) = 9.24, p = 0.0047 for drug x genotype; post-
hoc analysis, p < 0.0001 for WT vs. KO vehicle, p = 0.006 for KO vehicle vs. KO clozapine) 
(Fig 3C). This was also evident in the elevated plus maze, where clozapine treatment led to 
Lmtk3-KO mice spending less time in the open arms compared to vehicle treated mice (F(1,28) 
= 73.03, p < 0.0001 for genotype effect; F(1,28) = 63.43, p < 0.0001 for drug effect; F(1,28) = 
26.41, p < 0.0001 for drug x genotype; post-hoc analysis, p < 0.0001 for WT vs. KO vehicle, 
p < 0.0001 for KO vehicle vs. KO clozapine) (Fig. 3D). Treated Lmtk3-KO mice spent less 
time in the light chamber during the light-dark transition test (F(1,28) = 10.54, p = 0.0030 for 
genotype effect; F(1,28) = 6.662, p = 0.0154 for drug effect; F(1,28) = 4.321, p = 0.0469 for drug 
x genotype; post-hoc analysis, p = 0.0047 for WT vs. KO vehicle, p = 0.0160 for KO vehicle 
vs. KO clozapine) (Fig. 3E). Clozapine has notable success in treating PPI deficits (Gray et 
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al., 2009; Swerdlow & Geyer, 1993), therefore we also tested whether the PPI of Lmtk3-KO 
mice is recovered after treatment. Clozapine effectively reversed the deficits in PPI exhibited 
by Lmtk3-KO mice (F(1,84) = 68.47, p < 0.0001 for genotype effect; F(1,84) = 5.73, p = 0.018 
for drug effect; F(1,168) = 9.56, p = 0.0027 for drug x genotype; post-hoc analysis of KO 
vehicle vs. KO clozapine, p = 0.04 for 75dB,(p = 0.031 for 80 dB, p = 0.0221 for 85dB) (Fig. 
3F). There was no change in the sociability of Lmtk3-KO mice after clozapine treatment 
(F(1,28) = 16.08, p = 0.0004 for genotype effect, F(1,28) = 3.8, p = 0.0613 for drug effect, F(1, 28) 
= 0.05231, p = 0.8207 for drug x genotype) (Fig. 3G). The deficit in social novelty seen in 
Lmtk3-KO mice also remained after treatment (F(1,56) = 0.8147, p = 0.3706 for genotype 
effect, F(1,56) = 0.3708, p = 0.8196 for drug effect, F(1,56) = 2.361, p = 0.811 for drug x 
genotype) (Fig. 3H). This may be due to the ability of clozapine to increase social activity 
(Becker & Grecksch, 2003; Qiao et al., 2001), rather than attenuate. 
 
 




Figure 3. Clozapine suppresses the abnormal behaviour of Lmtk3-KO mice 
(A-C) Open field test (WT, n = 8; KO, n = 8).  ****P < 0.0001, ***P < 0.001, **P < 0.01, 
(ns) not significant; two-way ANOVA followed by Bonferroni’s test. (A) Clozapine reduces 
the locomotor activity of Lmtk3-KO compared to un-treated Lmtk3-KO. (B) Time spent 
within the centre region of the open field is reduced in Lmtk3-KO after clozapine treatment. 
(C) Less rearing occurs in clozapine-treated Lmtk3-KO vs. vehicle treated Lmtk3-KO. (D) 
Elevated plus maze (WT, n = 8; KO, n = 8). ****P < 0.0001, (ns) not significant; two-way 
ANOVA followed by Bonferroni’s test. Treated Lmtk3-KO spend less time in the open arms 
compared to vehicle treated mice. (E) Light-dark transition test (WT, n = 8; KO, n = 8). **P 
< 0.01, *P < 0.05, (ns) not significant; two-way ANOVA. Treated Lmtk3-KO mice spend less 
time in the light chamber of a light/dark box compared to vehicle treated. (F) Pre-pulse 
inhibition test. (WT, n = 8; KO, n = 8). *P < 0.05; repeated measures two-way ANOVA. 
Treated Lmtk3-KO display higher pre-pulse inhibition as compared to vehicle treated Lmtk3-
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KO.(G-H) Three-chamber social interaction test (WT, n = 8; KO, n = 8). **P < 0.01, *P < 
0.05, (ns) not significant; two-way ANOVA followed by Bonferroni’s test. (G) Lmtk3-KO 
mice remain hyper-sociable after clozapine treatment. (H) Clozapine treated Lmtk3-KO mice 
still exhibit social novelty deficits. 
 
Clozapine improves the memory and learning of Lmtk3-KO mice 
During the Morris water maze, treatment with clozapine 30 min prior to each training session 
improved the performance of Lmtk3-KO mice compared to untreated mice (F(1,168) = 25.26, p 
<0.0001 for genotype effect; F(1,168) = 20.15, p <0.0001 for drug x genotype) (Fig. 4A). 
Analysis of the probe test revealed a difference in the number of crossings of the trained 
quadrant by Lmtk3-KO mice after treatment, with a significant drug x genotype interaction 
(F(1,28) = 29.2, p <0.0001 ), though no significant values were found for genotype (F(1,28) = 
0.354, p = 0.5562) or drug effect (F(1,28) = 0.58, p = 0.452 ) (Fig. 4B). However, post-hoc 
analysis of the probe test revealed a significant difference between KO vehicle vs. KO 
clozapine (p = 0.0245). The same applied to time spent within the trained quadrant (F(1,28) = 
5.6, p = 0.025 for drug x genotype; F(1,28) = 1.2, p = 0.2702 for genotype effect; F(1,28) = 0.06, 
p = 0.799 for drug effect, post-hoc analysis, p = 0.045 for KO vehicle vs. KO clozapine) (Fig. 
4C). We did find that clozapine treatment showed a tendency toward some adverse effects 
during the probe test but statistical analysis revealed this was not significant (WT vehicle vs. 
WT clozapine (p = 0.181) for crossings of trained quadrant; WT vehicle vs. WT clozapine (p 
= 0.772) for time spent in trained quadrant). Lmtk3-KO mice exhibit impaired fear memory, 
but in the contextual and fear conditioning test, clozapine-treated mice exhibited higher levels 
of freezing compared to vehicle-treated mice in response to auditory cues (F(1,168) = 64.63, p = 
0.0001; for genotype effect; F(1,168) = 10.94, p < 0.0012; for drug effect; F(1,168) = 3.076, p = 
0.08 for drug x genotype) (Fig. 4D). This was also the case in response to contextual cues 
(F(1,168) = 12.67, p = 0.0005 for genotype effect; F(1,168) = 29.2, p <0.0001 for drug effect; 
F(1,168) = 12.31, p = 0.0006 for drug x genotype) (Fig. 4E). 
 




Figure 4. Clozapine improves the memory and learning of Lmtk3-KO mice  
(A-C) Morris water maze. (WT, n = 8; KO, n = 8). *P < 0.05; repeated measures two-way 
ANOVA (Fig. A) and two-way ANOVA followed by Bonferroni’s test (Fig. B, C). (A) 
Clozapine improves latency to find the hidden platform by Lmtk3-KO. (B) Increased number 
of crossings of the trained quadrant during the probe test by treated Lmtk3-KO compared to 
vehicle treated KO. (C) Longer time spent within the trained quadrant by treated Lmtk3-KO 
compared to vehicle treated KO. (D-E) Auditory and contextual fear conditioning test. (WT, 
n = 8; KO, n = 8), repeated measures two-way ANOVA. (D) Clozapine treatment increases 
the freezing response to auditory cues of Lmtk3-KO in comparison to un-treated KO mice. 
(E) Clozapine increases the freezing response to contextual cues by Lmtk3-KO in comparison 
to un-treated KO mice 
 
Long-term potentiation is impaired in Lmtk3-KO mice 
LTP is a form of synaptic plasticity involving the strengthening of synaptic transmissions 
after repetitive stimulation. Dysfunctional LTP leads to a number of behavioural 
abnormalities and cognitive issues (Pittenger, 2013; Stuchlik, 2014). As Lmtk3-KO mice 
display severe cognitive impairments, we performed electrophysiological analysis of the CA1 
region of the hippocampus to measure LTP. Theta-burst stimulation of Schaffer collaterals 
was used to induce LTP and output was recorded by measuring field EPSPs (excitatory post-
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synaptic potentials). The recordings revealed that stimulation failed to elicit LTP in Lmtk3-
KO mice compared to WT mice (Fig. 5A). The average fEPSP slope was significantly lower 
(p < 0.01) in Lmtk3-KO mice (111.8 ± 10.09% of baseline) compared to WT (146.8 ± 
6.530% of baseline) (Fig. 5B).  
 
 
Figure 5. LTP is impaired in Lmtk3-KO mice 
(A) Time course of LTP induced by theta-burst in WT (open circle) and Lmtk3-KO (closed 
circle). Theta-burst stimulation was applied at time 0 min. Inset: representative traces 
recorded at times indicated on the graph. (B) LTP calculated as % of the mean EPSP slope 
recorded from 50 to 60 min after theta-burst stimulation relative to that during the control 
period. **P < 0.01, un-paired two tailed t-test. (WT, n = 12; KO, n = 8). All values represent 
means ± SEM. 
 
Loss of LMTK3 leads to abnormal GluA1 trafficking 
Trafficking of AMPARs to post-synaptic sites is essential for regulating LTP, and controls 
memory formation and memory loss (Dong et al., 2015). In addition AMPAR-KO mice, 
particularly those lacking the GluA1 subunit, exhibit a schizophrenia and schizoaffective 
phenotype (Barkus et al., 2012; P. J. Fitzgerald et al., 2010). As LTP is impaired in Lmtk3-
KO mice, we wished to investigate whether changes in AMPAR trafficking could be 
responsible. After treatment of cultured neurons with AMPA, the definitive agonist for 
AMPARs, there was less GluA1 on the surface of Lmtk3-KO neurons, compared to WT, 15 
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min post-treatment (Fig. 6A, 6B). No difference in the GluA2 subunit was observed. An 
‘antibody feeding’ immunofluorescence assay also revealed lower levels of surface GluA1 in 
Lmtk3-KO neurons, in addition to increased intracellular GluA1 (Fig. 6C, 6D). As GluA1 
trafficking is rapid, we investigated surface and internalized levels of GluA1 at 5, 10, and 15 
min post-AMPA treatment. In WT neurons, there is a reduction of GluA1 surface expression 
5 min post-treatment, which recovers by 15 min, whereas in Lmtk3-KO neurons, there is 
significantly less change (Fig. 6E, 6F). We found that the loss of surface GluA1 in WT 
neurons coincided with increased internalized GluA1, and vice versa, as surface GluA1 
recovers when internalized GluA1 is reduced 15 min post treatment (Fig. 6G, 6H). This 
follows the basic model of LTP, where internalization of AMPARs from extra-synaptic sites, 
followed by transport back to the post-synaptic membrane, occurs in response to stimulation 
(Anggono & Huganir, 2012; Citri & Malenka, 2008). However, in Lmtk3-KO neurons, there 
is significantly less internalization of surface GluA1, and this internalization occurs at a 
slower rate. Intracellular GluA1 accumulates after 10 min, which remains 15 min post-
treatment, indicating an inability to transport GluA1 to the surface. In accord, surface GluA1 
does not recover after 15 min. Total and phosphorylated GluA1 does not change, suggesting 
that impairment of the endocytic pathway is primarily responsible (Fig. 6I). Previous reports 
found LMTK3 to be both on the membrane surface and in transferrin-positive endosomes, 
indicating that it is internalized in the same endocytic pathway as GluA1 (Inoue et al., 2014; 
Zheng et al., 2015). Co-IP revealed that LMTK3 binds GluA1, leading us to hypothesize that 
LMTK3 links GluA1 to the endocytic machinery (Fig. 6J).  
 
 




Figure 6. Abnormal GluA1 trafficking in Lmtk3-KO neurons 
(A-B) Surface biotinylation was performed on cortical and hippocampal neuronal cultures as 
described in the Methods. (A) Representative immunoblot of surface GluA1 and GluA2 in 
neurons treated with 100 M AMPA for 15 min or un-treated (basal), reveals less surface 
GluA1 in Lmtk3-KO neurons after AMPA treatment. No change to GluA2 expression is 
observed. (B) Quantification of immunoblot as fold change compared to WT. (WT, n = 4; 
KO, n = 4).*P < 0.05, un-paired two tailed t-test . (C-D) Cultured neurons labelled with 
GluA1 antibody using the ‘antibody feeding’ method. Neurons were treated with 100 M 
AMPA for 15 min or left un-treated (basal). Fluorescent staining reveals GluA1 surface 
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expression (green) and intracellular expression (red). (C) No difference in GluA1 on the 
surface or intracellular in un-treated neurons. (D) Surface GluA1 is reduced and intracellular 
GluA1 is enhanced in Lmtk3-KO neurons. (E-F) Changes in GluA1 surface expression after 
100 M AMPA treatment for described times. (E) Surface GluA1 decreases 5 min after 
treatment and recovers by 15 min in WT neurons. Minimal effect on surface GluA1 is 
observed in Lmtk3-KO neurons. (F) Quantification as fold change compared to WT. (WT, n = 
4; KO, n = 4). *P < 0.05, **P < 0.01; un-paired two tailed t-test. (G-H) Level of internalized 
GluA1 after 100 M AMPA treatment for the described times. (G) In WT neurons, GluA1 
internalization increases 10 min after AMPA treatment then drops by 15 min. In Lmtk3-KO 
neurons, internalization of GluA1 occurs 10 min after AMPA treatment and remains after 15 
min. (H) Quantification as fold change compared to WT. (WT, n = 4; KO, n = 4). *P < 0.05, 
**P < 0.01; un-paired two tailed t-test. (I) Total and phosphorylated GluA1 in WT and 
Lmtk3-KO neurons. No significant difference between genotypes. (J) Co-IP using anti-
LMTK3 antibody with whole brain lysate reveals that LMTK3 binds GluA1. 
 
Decreased expression of GluA1 in the post-synaptic density of Lmtk3-KO mice 
An impairment in the transport of GluA1 from an internal pool to the post-synaptic surface 
should result in a deficit of GluA1 at post-synaptic sites. To investigate this we performed 
synaptosomal fractionation on forebrain tissue. A significant reduction in the expression of 
GluA1 within the post-synaptic density of Lmtk3-KO mice was discovered (Fig. 7A, 7B). 
Interestingly, analysis of Lmtk3-KO mice treated with clozapine showed that GluA1 
expression in the post-synaptic density was equivalent to that of WT mice, 30 min after 
clozapine injection (Fig. 7C, 7D). The reason for this recovery remains unclear but may 
explain how clozapine attenuates the behaviour of Lmtk3-KO mice. 
 





Figure 7. Reduced GluA1 expression in the PSD of Lmtk3-KO mice  
(A) Synaptosomal fractionation was conducted on forebrain tissue of WT and Lmtk3-KO 
mice as described in Methods (n = 3). Representative immunoblot of different fractions 
probed with PSD95 (post-synaptic marker), synaptophysin (pre-synaptic marker), LMTK3, 
and GluA1 are shown. The PSD fraction of Lmtk3-KO mice shows lower GluA1 levels 
compared to WT. (B) Quantification as fold change compared to WT. **P < 0.01; un-paired 
two tailed t-test. (C) Synaptosomal fractionation of forebrain tissue derived from clozapine-
treated mice (n = 3). No significant difference in GluA1 expression between genotypes. (D) 










Modelling human psychiatric disease in animals is challenging, given the objective nature of 
symptoms and diagnostic tests. Nonetheless, there is a consensus that an effective animal 
model of mental illness displays phenotypes closely resembling human symptoms and mimic 
human responses to pharmacological treatment (Chadman et al., 2009). Here we show that 
Lmtk3-KO mice present abnormal behaviour such as deficits in PPI, loss of novelty 
preference and cognitive dysfunction that are associated with psychiatric disease, primarily 
schizophrenia and bipolar disorder. Reports have shown that schizophrenia and bipolar 
disease are closely linked and often overlap (Forstner et al., 2017; Laursen et al., 2009). 
Hyper-sociability in the three-chamber social interaction test is also displayed, which is 
surprising, as this is not commonly observed in conjunction with the other abnormal 
behaviours displayed by Lmtk3-KO mice. Though this is the case, there are a number of 
mouse models with mutations in genes altering AMPAR function which display hyper-
sociability similar to that of Lmtk3-KO mice (Barkus et al., 2012; Han et al., 2017; Tanda et 
al., 2009). We hypothesize that the hyper-sociability of Lmtk3-KO may be a consequence of 
abnormal AMPA receptor function. It should also be stated that Lmtk3-KO mice show lower 
levels of depression-like symptoms (Inoue et al., 2014), even though elevated depression is 
often co-morbid with schizophrenia (Samsom & Wong, 2015). Instead, lower levels of 
depression can be found in animal models of bipolar disease (Logan & McClung, 2016), 
highlighting the overlap between schizophrenia and bipolar associated behaviour in Lmtk3-
KO mice. In addition it has been found that cell specific deletion of GluA1 led to no change 
in depression-like behaviour of mice, as opposed to global deletion of GluA1 which causes a 
significant rise (Vogt et al., 2014). Future work should be conducted to analyse the effect of 
Lmtk3 depletion on GluA1 within specific regions of the brain and cell types, to determine 
whether this could play a part in the extreme range of behaviours observed in Lmtk3-KO 
mice.  
Lmtk3-KO mice respond well to acute treatment with clozapine, an antipsychotic commonly 
used to treat schizophrenia and schizoaffective disorders. Clinically, chronic drug treatments 
are required for efficacy in psychiatric patients, and further investigation is required to 
determine the effect of chronic administration in Lmtk3-KO mice. Our study reveals that 
Lmtk3-KO mice express lower levels of GluA1 in the forebrain, specifically in the post-
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synaptic region. Surprisingly, treatment of Lmtk3-KO mice with clozapine increased GluA1 
expression. The reason for this is still under investigation, hindered by the fact that 
clozapine's mechanism of action is unclear. A number of studies have shown that clozapine 
treatment of rodents induces changes in expression of a range of glutamate receptors, 
including AMPARs, which may account for the upregulated GluA1 in treated Lmtk3-KO 
mice (L. W. Fitzgerald et al., 1995; Meshul et al., 1996).  
In Lmtk3-KO neurons, we observed reduced trafficking of GluA1 after stimulation with 
AMPA. As we wished to concentrate on the effect of LMTK3 depletion specifically on 
AMPA receptors, we did not use standard chemical LTP protocols, bypassing the effect of 
activating NMDA and other receptors on AMPA trafficking. Our previous report showed that 
surface expression of GluA1 and GluA2 in cultured neurons, was not affected by the loss of 
LMTK3; however, these experiments were conducted under basal conditions (Inoue et al., 
2014). Trafficking of GluA1 is activity-dependent, and low levels of recycling occurs under 
basal conditions (Shi et al., 2001). We hypothesize that LMTK3 is involved in the 
endocytosis and recycling of GluA1, and maybe required to guide early endosomes into the 
recycling pathway. Consequently, internalized GluA1 accumulates in neurons lacking 
LMTK3 after AMPA stimulation. Trafficking of GluA2, the other major AMPAR subunit, is 
not influenced by the loss of LMTK3, which could be due to differences in the activation and 
trafficking between GluA1 and GluA2. The exact mechanism by which LMTK3 influences 
GluA1 trafficking is still unknown, but we speculate that it may perform as a scaffold protein 
between endocytic vesicles and GluA1. This is based on the finding that LMTK3 interacts 
with both GluA1 and the clathrin-adaptor protein AP2. An interaction between GluA1 and 
AP2 is necessary for the trafficking of GluA1 (Petrini et al., 2009). Mice lacking expression 
of GluA1 have been described as a schizophrenia and schizoaffective mouse model and 
exhibit a range of behaviours similar to that of Lmtk3-KO mice (Wiedholz et al., 2008). In 
addition it has been shown that in the frontal cortex of elderly schizophrenia patients, GluA1 
accumulates in early endosomes, due to defects in the recycling pathway (Hammond et al., 
2010). Lmtk3-KO mice present increased levels of dopamine metabolites in the striatum, yet 
no changes in the level of dopamine or tyrosine hydroxylase were found, and neither were 
there changes in the phosphorylation state of DARP32 (Inoue et al., 2014). Therefore, we 
believe dopamine turnover is indirectly affected by depletion of LMTK3, and does not alter 
dopaminergic signalling or contribute to the phenotype of Lmtk3-KO mice. Although 
hyperactivity is generally associated with an increase in dopamine, there are examples where 
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cell-specific changes in GluA1 or treatment with NMDA receptor antagonists can cause 
hyperactivity independent of dopamine elevation (Chartoff et al., 2005; Inta et al., 2014).  
LTP is the most established model of synaptic plasticity, and is characterized by an increase 
in GluA1 on the post-synaptic surface (Bassani et al., 2013). A pool of recycling endosomes 
containing GluA1 supply this increase (Park et al., 2004). As GluA1 recycling is impaired in 
Lmtk3-KO neurons, it is reasonable that LTP is severely impaired in Lmtk3-KO mice. It is 
generally accepted that LTP is vital for memory formation and storage (Stuchlik, 2014). 
Moreover, there are reports that schizophrenia patients, as well as established mouse models 
of psychiatric disease display disrupted LTP (Balu et al., 2013; Frantseva et al., 2008; Kvajo 
et al., 2008). We hypothesize that impaired LTP is an important factor in the change of 
behaviour in Lmtk3-KO mice. 
To date, only one mutation in LMTK3 has been found in a psychiatric patient, specifically in 
an autistic child (Iossifov et al., 2012). Autism spectrum disorder (ASD) share phenotypical 
and genetic similarities with a number of psychiatric diseases including schizophrenia and 
bipolar disease (Voineagu et al., 2011). Patients diagnosed with ASD often develop psychotic 
symptoms reminiscent of schizophrenia (Canitano & Pallagrosi, 2017). Lmtk3 is also 
recognized as a Fragile X mental retardation protein (FMRP) target (Nebel et al., 2016). 
FMRP is an RNA binding protein, which regulates a number of neuronal processes including 
synaptic plasticity. Loss of FMRP leads to Fragile X syndrome which is characterized by 
severe mental retardation and reports have shown that expression of FMRP and its targets are 
altered in a number of psychiatric diseases (Fatemi & Folsom, 2011; Fernandez et al., 2013). 
Little is known about the expression levels of LMTK3 in psychiatric patients, and it would be 
interesting to see if alterations in LMTK3 levels can be found in patients. 
Our data further develops the hypothesis that the glutamatergic system plays a vital role in 
the maintenance of mental health. It is clear that Lmtk3-KO mice display abnormal 
behaviour, that which commonly associate with psychiatric disease. Therefore, they could be 
a useful model in the study of behaviour and learning. In addition, Lmtk3-KO mice display a 
human-like response to clozapine, which is ideal for testing the efficacy of new 
pharmaceuticals. Future work is required to clarify the mechanism by which LMTK3 controls 
GluA1 trafficking, to further understand the molecular pathways involved in psychiatric 
disease 
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